Astrazeneca (AZN) Inventory Average (2009 - 2026)

Astrazeneca's Inventory Average history runs 18 years deep, the most recent figure standing at $6.6 billion for Q1 2026.

• In Q1 2026, Inventory Average rose 17.5% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 17.5% YoY), while the FY2025 annual figure was $5.9 billion, up 10.58% from the prior year.
• Inventory Average was $6.6 billion for Q1 2026 at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $8.3 billion in Q1 2022 to a low of $4.8 billion in Q1 2023.
• Historically, Inventory Average has averaged $5.9 billion across 5 years, with a median of $5.6 billion in 2025.
• Biggest YoY gain for Inventory Average was 156.81% in 2022; the steepest drop was 49.89% in 2022.
• A 5-year view of Inventory Average shows it stood at $4.9 billion in 2022, then increased by 9.6% to $5.4 billion in 2023, then increased by 2.18% to $5.5 billion in 2024, then increased by 20.09% to $6.6 billion in 2025, then decreased by 0.17% to $6.6 billion in 2026.
• The last three Inventory Average figures came in at $6.6 billion (Q1 2026), $6.6 billion (Q4 2025), and $6.5 billion (Q3 2025), per Business Quant data.